1月BD交易远超预期本以为会进入调整期，却迎来了再次爆发。
而五和博澳目前锚定约40亿元估值。若以其2025年前九个月2.08亿元的营收推算，其市销率或远超荣昌生物等成熟Biotech的6-8倍区间，甚至显著高于信达生物与康方生物的行业标杆水平。
，这一点在Line官方版本下载中也有详细论述
"I told him not to participate. Things can happen at protests," she told the BBC. But Shreeyam was deeply engaged with politics, his father said. "He said corruption had hollowed out [Nepal]. He was far more informed than I was."
Buy a cartoon | David’s favourite work of 2025